Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease

Skip to main content Overview News Events & Presentations Stock Info Stock Quote Stock Chart Analyst Coverage Financials Quarterly Results SEC Filings Governance Governance Documents Executive Management Board of Directors Scientific Advisory Board Committee Composition Resources Information Request Form Investor Email Alerts Investor Contacts Overview News Events & Presentations Stock Info Stock Quote Stock Chart Analyst Coverage Financials Quarterly Results SEC Filings Governance Governance Documents Executive Management Board of Directors Scientific Advisory Board Committee Composition Resources Information Request Form Investor Email Alerts Investor Contacts Search Search query Search Search query Overview News Events & Presentations Stock Info Back Stock Quote Stock Chart Analyst Coverage Financials Back Quarterly Results SEC Filings Governance Back Governance Documents Executive Management Board of Directors Scientific Advisory Board Committee Composition Resources Back Information Request Form Investor Email Alerts Investor Contacts News Details View All News Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease July 9, 2026 Download (opens in new window) https://www.globenewswire.com/news-release/2026/07/09/3325085/0/en/serina-therapeutics-announces-completion-of-sentinel-dosing-in-cohort-1-of-phase-1b-registrational-trial-of-ser-252-for-advanced-parkinson-s-disease.html View All News Contact Us CONTACT US BY PHONE at (256) 327-9630 Send Email Quick Links SEC Filings opens in new window Information Request Form opens in new window Investor Email Alerts Investor Email Alerts Personal Information Email Address * Required Email Address is required. Email Address is invalid. Investor Alert Options * News Quarterly Reports Annual Reports SEC Filings End of Day Stock Quote Events & Presentations Investor Alert Options is required. The captcha test has failed. Please try again. Sign Up Unsubscribe © 2026 Serina Therapeutics, Inc. - All rights reserved Powered By Q4 Inc. 5.182.1.3 (opens in new window) Privacy Policy opens in new window | Cookies Policy opens in new window | Site Map opens in new window (Opens in new window)